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Background:
•
Psoriasis is one of the most
common skin conditions in the
United States affecting more
than 8 million people.
•

•

•

•

High amounts of vitamin D has
been shown to be effective in
treatment of psoriasis. It also
has a well-documented safety
profile at the doses and
duration that will be used
during this study.
Triamcinolone and other topical
corticosteroids are considered
a first line treatment for mild to
moderate psoriasis with a welldocumented safety profile.
Individually both of these
medications have shown
effectiveness in the
management and treatment of
mild to moderate psoriasis.
This study is designed to test
whether a combination therapy
of topical 0.1% triamcinolone
with 40,000 IU vitamin D3 daily
is effective in treating mild to
moderate psoriasis.

Results:
Methods:
Preliminary analysis of 5 subjects showed a
•
To test this, we planned to
•
enroll up to 24 subjects whom
consistent decrease of PASI score from initial
are age 18 and older with mild
screening appointment (average score of
to moderate psoriasis (2%+
6.42) to final appointment on week 24
PASI).
(average score of 4.72).
•

•

•

Currently, we have 7 subjects •
enrolled These subjects will be
treated with topical 0.1%
triamcinolone and oral 40,000
IU vitamin D3.
•
The patients were monitored
monthly until completion of
trial at 6 months.
During the 6-month period,
patients had monthly blood
draws (CBC, CMP, iPTH, 25hydroxyvitamin D, 1,25
dihydroxyvitamin D), PASI
scores (self-calculated), sPGA
(self-calculated), Quality of
Life assessment (DLQI), PHQ9, vital signs, height and
weight

There was a modest decrease in sPGA for all
subjects with an average starting sPGA of 2.6
and an average final sPGA of 2
There was a modest improvement in PHQ9
for all patients with a starting average score
of 6 and a final average score of 3. Further,
there was a mild improvement in DLQI score
with a starting average score of 3 and a final
average score of 2.25.

•

From a lab value perspective, there were no
patients with recorded hypercalcemia or
other recorded electrolyte or metabolic
derangements throughout the duration of the
study. (average Calcium: 9.5).

•

There was a moderate average increase in 25hydroxyvitamin D levels (starting average
value: 24, final average value: 68). Finally,
there was a modest decrease in average iPTH
with an average starting value of 50.6 and an
average final value of 23.
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6.42
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2

Conclusions:
• Vitamin D combined with
triamcinolone showed a
decrease in PASI and SGA in
several patients with
psoriasis.
• While preliminary results are
encouraging, more subjects
are needed to make
definitive conclusions on the
efficaciousness of vitamin D
combined with triamcinolone
in patients with mild to
moderate psoriasis.
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